Egyptian International Pharmaceutical Industries Co 2024 AR2
The report highlights the financial and operational performance of Egyptian International Pharmaceutical Industries Company (EIPICO) for the fiscal year 2024. EIPICO achieved a net profit of EGP 1.022 billion, representing a 40% growth compared to the previous year, with total sales reaching EGP 7.364 billion. The company maintained its leading position in Egyptian pharmaceutical exports, reaching 62 countries with export sales of USD 54.7 million. EIPICO made significant progress on its EIPICO 3 factory project, reaching 95% completion, which will be the first in the MENA region to fully manufacture biosimilars and biologicals. Additionally, the company advanced its digital transformation through the implementation of SAP, Pharma 4.0, and LIMS, while aligning its operations with 12 UN Sustainable Development Goals.
Company: Egyptian International Pharmaceutical Industries Co
Sector: Health Care
Country: Egypt
Year: 2024
Type: AR2
Pages: 113
Egyptian International Pharmaceutical Industries Co
Annual Report
The report highlights the financial and operational performance of Egyptian International Pharmaceutical Industries Company (EIPICO) for the fiscal year 2024. EIPICO achieved a net profit of EGP 1.022 billion, representing a 40% growth compared to the previous year, with total sales reaching EGP 7.364 billion. The company maintained its leading position in Egyptian pharmaceutical exports, reaching 62 countries with export sales of USD 54.7 million. EIPICO made significant progress on its EIPICO 3 factory project, reaching 95% completion, which will be the first in the MENA region to fully manufacture biosimilars and biologicals. Additionally, the company advanced its digital transformation through the implementation of SAP, Pharma 4.0, and LIMS, while aligning its operations with 12 UN Sustainable Development Goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English, Arabic
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees